Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

摘要: Objective An examination of clinically relevant subgroups patients in the MARINA study ranibizumab treatment minimally classic or occult with no choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) was done. Objectives were determine effectiveness across subgroups, compare that sham injection within and evaluate relationship between selected baseline characteristics visual acuity (VA) outcomes. Design Retrospective subgroup analyses 24-month data from study. Participants Controls Seven hundred sixteen randomly assigned 0.3 mg (n = 238), 0.5 240), 238). Methods Efficacy outcomes compared based on patients' gender, age, VA score, CNV lesion size, type, duration neovascular AMD using univariate analyses. Multivariate performed change 24 months score assess further correlation outcome. Main Outcome Measures Proportion losing Results For each 3 end points, all ranibizumab-treated did better average than sham-treated patients. Increasing larger size at baseline, a higher associated greater loss letters group less gain groups. However, net benefit versus who scored those lower VA. Conclusions This analysis indicates an increase evaluated, superior subgroups. The most important predictors were, decreasing order importance, age.